Insomnia is present in nearly half of heart disease patients, according to research presented at ESC 2022 and published in SLEEP Advances.
The prospective study collected data on insomnia, risk factors for repeat heart events, and co-existing conditions from 1,068 patients for an average of 16 months after a heart attack and/or a procedure to open blocked arteries (stent implantation or bypass surgery).
Participants completed the Bergen Insomnia Scale questionnaire which is based on the diagnostic criteria for insomnia. Six questions cover the ability to fall asleep and stay asleep, waking up prematurely, feeling inadequately rested, tiredness during the day that affects ability to function at work or socially, and being dissatisfied with sleep.
The risk factors included C-reactive protein (a marker of inflammation), smoking status, low-density lipoprotein (LDL) cholesterol, diabetes, physical activity, waist circumference, and systolic blood pressure. The co-existing conditions were stroke, transient ischemic attack, peripheral artery disease, and kidney failure.
Patients were followed for the primary composite endpoint of major adverse cardiovascular events (MACE), defined as cardiovascular death, hospitalization due to myocardial infarction, revascularization, stroke or heart failure. Outcome data were obtained from hospital records.
Approximately one in five participants (21%) were women. At baseline, the average age of patients was 62 years, almost half (45%) had insomnia and 24% had used sleep medication in the past week. During an average follow-up of 4.2 years, a total of 364 MACE occurred in 225 patients.
Compared to those without insomnia, the relative risk of recurrent MACE in patients with insomnia was 1.62 after adjusting for age and sex, 1.49 after additional adjustment for coronary risk factors, and 1.48 after also adjusting for co-existing conditions. The association between insomnia and recurrent MACE remained significant when symptoms of anxiety and depression were also adjusted for, with a relative risk of 1.41.
Insomnia accounted for 16% of recurrent MACE in attributable risk fraction analyses, being third in importance after smoking (27%) and low physical activity (21%). Mr. Frojd said: “This means that 16% of recurrent major adverse cardiovascular events might have been avoided if none of the participants had insomnia.”
“Sleep problems are linked to mental health issues, but our study found that insomnia was still significantly associated with heart events even after accounting for symptoms of anxiety and depression,” said lead author Lars Frojd, a medical student at the University of Oslo, Norway. “The findings suggest that heart patients should be assessed for insomnia and offered appropriate management.”
He concluded: “Our study indicates that insomnia is common in heart disease patients and is linked with subsequent cardiovascular problems regardless of risk factors, co-existing health conditions and symptoms of mental health. Further research is needed to examine whether insomnia treatments such as cognitive behavioral therapy and digital applications are effective in this patient group.”